The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Novo Nordisk (NVO) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Novo Nordisk currently has an ...

Watch out, Novo Nordisk (NVO -1.38%) shareholders -- there's yet another new competitor on the scene that could one day unseat the likes of Ozempic and Wegovy as a leading treatment for type 2 diabetes and obesity. It's a next-gen weight loss pill being developed by a company you already know about: Novo Nordisk.That's right, according to the Danish pharma giant's presentation on Thursday at the Capital Markets Day 2024 event, it has a candidate in early clinical trials that preliminarily appears to be even ...

Novo Nordisk (NVO) ended the recent trading session at $131.24, demonstrating a -1.38% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.11%. Meanwhile, the Dow experienced a rise of 0.12%, and the technology-dominated Nasdaq saw a decrease of 0.41%.The drugmaker's shares have seen an increase of 9.79% over the last month, surpassing the Medical sector's gain of 3.03% and the S&P 500's gain of 2.7%.The upcoming earnings release of Novo Nordisk wi ...

Novo Nordisk (NVO) announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion for Wegovy (semaglutide 2.4 mg) to reduce the risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack or stroke in adults with either overweight or obesity and established cardiovascular disease.Wegovy, a GLP-1 agonist, is Novo Nordisk’s blockbuster chronic weight management injection approved for adults with obesity or overweight. Th ...

Shares of Novo Nordisk (NVO -2.10%) rose to a new all-time high on Thursday, March 7. The market was responding to encouraging results from a clinical trial with an experimental weight-management drug called amycretin.Amycretin is an orally available treatment candidate, which could give it a big leg up if it eventually earns approval. Novo Nordisk's Wegovy and Eli Lilly's (LLY -2.31%) Zepbound are racking up billions in annual sales as weekly injectables.Is Novo Nordisk a buy now? Let's look at the path ah ...

The popular weight-loss drug Wegovy, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, federal regulators said Friday.The Food and Drug Administration approved a label change requested by drugmaker Novo Nordisk that expands the use of semaglutide.The decision was based on the results of a study that found that Wegovy cut the risk of serious heart problem ...

Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023.The Food and Drug Administration approved Novo Nordisk's blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart disease, the company said Friday. That decision could widen insurance coverage for the drug and similar treatments for obesity, which has been a major barrier to access for patients. The appro ...

Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday said the company's experimental weight loss pill, amycretin, could eventually become a best-in-class treatment for obesity. The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy by developing a new generation of treatments for obesity, including more convenient and potentially cheaper pills. His remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin. Pat ...

Novo Nordisk (NVO) shares climbed about 9% on Mar 7 and continued to gain another 1.4% in the after-market hours, following the company’s presentation of efficacy data from a phase I study on its new oral obesity pill, amycretin, at its Capital Markets Day.In the completed phase I study of oral amycretin, it was observed that the treatment of patients with amycretin resulted in a reduction of 13.1% in body weight compared with a decrease of 1.1% in the placebo arm after 12 weeks. Amycretin has shown faster ...

The logo of Danish pharmaceutical company is pictured at their headquarters in Bagsvaerd outside of Copenhagen, Denmark on February 1, 2017.Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday, after fresh early trial data showed positive results for its new experimental weight loss pill.Shares of the Danish company hit a record high in the previous session, rallying by as much as 8%, after telling investors that a Phase I trial of the company's amycretin pill showed 13.1% weight ...